Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.
Angie Maynard, PharmD, MS, BCOP
Advertisement
Angie Maynard, PharmD, MS, BCOP, is an assistant professor at Lipscomb University.
Articles by Angie Maynard, PharmD, MS, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Senate Unveils Sweeping Bill to Reform 340B Drug Program
2
Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD
3
Brexpiprazole and Dextromethorphan-Bupropion: Mechanisms of Action and Key Clinical Trial Data for Approved Alzheimer's Disease Agitation Therapies
4
Trump Childhood Vaccine Order: What It Means for Parents and Payers
5